Literature
首页医源资料库在线期刊美国临床营养学杂志2003年77卷第4期

Dietary supplements and functional foods: 2 sides of a coin?

来源:《美国临床营养学杂志》
摘要:ABSTRACTDietarysupplementsareusedbymorethanone-halfoftheadultUSpopulation。Incontrasttopharmaceuticals,dietarysupplementsmaybesoldintheUnitedStateswithlittleregulationotherthanlistingofingredientsandthepotentialhealthbenefits。Mostherbalusersdonotinform......

点击显示 收起

Charles H Halsted

1 From the Department of Internal Medicine and Nutrition, University of California, Davis.

2 Presented at the Third Heelsum International Workshop, held in Heelsum, the Netherlands, December 10–12, 2001.

3 Reprints not available. Address correspondence to CH Halsted, Department of Internal Medicine and Nutrition, University of California, Davis, TB 156, One Shields Avenue, Davis, CA 95616, United States. E-mail: chhalsted{at}ucdavis.edu.


ABSTRACT  
Dietary supplements are used by more than one-half of the adult US population. In contrast to pharmaceuticals, dietary supplements may be sold in the United States with little regulation other than listing of ingredients and the potential health benefits. By contrast, herbal products in Germany are carefully regulated by the same standards as drugs, and efforts are under way to standardize their regulation in the entire European Union. Most herbal users do not inform their physicians that they are taking these supplements, and most physicians do not inquire. Although some herbal products have clinically proven benefits, it is increasingly apparent that many contain potentially toxic substances, particularly in relation to interactions with drugs. Hence, it is essential that practicing physicians develop a working knowledge of herbals—specifically, about claims for their usage and potential or proven efficacies and toxicities—and that they incorporate such knowledge into the evaluation and management of their patients. By contrast, functional foods—integral components of the diet that are understood to contribute added health benefits—are the subject of intense and widespread research in food and nutritional science. Examples include many polyphenolic substances, carotenoids, soy isoflavones, fish oils, and components of nuts that possess antioxidant and other properties that decrease the risk of vascular diseases and cancer. Practicing physicians are advised to stay abreast of these emerging findings in order to best advise their patients on the value of health-promoting diets in disease prevention.

Key Words: Dietary supplements • herbal products • functional foods • challenges to medical practitioners


INTRODUCTION  
In 1994 the US Congress enacted the Dietary Supplement Health and Education Act (DSHEA) (1). This act defines a dietary supplement as "a product (other than tobacco) that is intended to supplement the diet and that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total daily intake, or a concentrate, metabolite, constituent, extract or combinations of these ingredients." Furthermore, a dietary supplement is intended for ingestion in pill, capsule, tablet, or liquid form; is not represented for use as a conventional food or as the sole item of a meal or diet; and is labeled as a dietary supplement (1). In a recent Science forum, Zeisel (2) provided 2 additional, useful working definitions. A neutraceutical can be defined as "a diet supplement that delivers a concentrated form of a biologically active component of food in a non-food matrix to enhance health." The US Food and Drug Administration (FDA) does not recognize the term neutraceutical. Functional foods, according to Zeisel, are not dietary supplements but rather "are consumed as part of a normal diet and deliver one or more active ingredients (that have physiologic effects and may enhance health) within the food matrix" (2).

Dietary supplements
Among his "bedside teachings," Sir William Osler stated, "The desire to take medicines is one feature which distinguishes man, the animal, from his fellow creatures" (3), a viewpoint recently corroborated by the finding of medicinal herbs in the intestine of the 5300-y-old frozen "iceman" who was recently discovered in the Swiss Alps (4). Botanicals with medicinal properties have been used from time immemorial in all cultures and, with the introduction of ingredient assays and standards in the early 20th century, form the foundation for modern Western pharmacology (5). On the other hand, the consumption and market value of herbs and other nutritional supplements has reached astonishing proportions in the United States. According to recent FDA testimony, dietary supplements, including vitamins, were consumed by 158 million Americans in the year 2000—that is, more than half the US population (6). This compares with a 1997 survey that showed that alternative medical therapies, principally herbals, were used by 83 million people (7). In 2000, the total dietary supplement market included 32% as herbals and 38% as vitamins. The sales of dietary supplements in the United States doubled after passage of the DSHEA in 1994, to $17.1 billion in 2000, and are anticipated to continue increasing by 10% per year (5).

Although the FDA was charged with implementing stringent governmental regulations for ensuring the accurate labeling, safety, and efficacy of drugs, the food supplement industry was under no specific regulations until the Nutrition Labeling and Education Act of 1990, which permitted health claims for nutritional supplements that were restricted to several categories, including osteoporosis, hypertension, heart disease, and cancer. Spurred by intensive industry lobbying, Congress passed the DHSEA in 1994 to broaden the availability of all dietary supplements by authorizing their claims for functional specific health benefits, but not specific disease prevention or cure. The FDA established a Center for Food Safety and Applied Nutrition (CFSAN) with responsibility for oversight of new supplemental products, including the marketing of clearly identified products declared to be of known composition and strength. New dietary supplements are reviewed by the FDA under the rubric of the same good manufacturing practice regulations that apply to conventional foods. The manufacturer is responsible for ensuring that the "supplement facts" label and ingredient lists are accurate, that the dietary ingredients are safe, and that the content matches the amount declared on the label. However, the FDA does not require accurate chemical analyses as a basis for the identification and quantification of ingredients. The label must also contain the disclaimer, "This product is not intended to diagnose, treat, cure, or prevent any disease." This policy bypasses the usual FDA procedures of requiring proof of safety from the manufacturer before approval of a drug for public consumption, and puts the postmarketing burden of proving significant risk on the FDA. Supplements that were produced before 1994 are assumed safe, whereas the safety of those marketed after 1994 is the responsibility of the manufacturers. The specifics of the role of the FDA in regulating dietary supplements can be found in a recently posted website: http://www.cfsan.fda.gov/dms/ds-oview.html (8).

How frequently do people use dietary supplements? A 2001 survey of 376 randomly selected adults living in Minneapolis found that 61.2% used supplements, most commonly ginseng. Few were advised by their physicians, and most obtained information on herbs from family, friends, or the Internet. Although the promotion of well-being was given as the main reason for herbal usage, fewer than 60% found satisfaction (9). A survey of 118 patients attending 16 different family practices in Calgary, Canada, found vitamin, mineral, or herbal supplement usage among 79% of women and 44% of men, and that 25% of those over age 50 and 70% of those under age 50 chose not to inform their physicians. Based on Internet information, the younger patients believed that supplements were safer and more effective than prescription drugs (10). Among 242 pregnant women, 25% had used herbals on a regular basis—typically garlic, echinacea, and ginseng—before pregnancy, and 9% continued herbal use during pregnancy (11). A study of women with early-stage breast cancer found that the usage of alternative medicine had increased from 10.6% before diagnosis to 28.1% after diagnosis and initiation of therapy, and that that increase was associated with depression and fear of cancer recurrence. Of interest, one-third of this group hid their alternative approaches from their physicians (12). An accompanying editorial suggested that widespread marketing and a lack of physician interest in dealing with or time to address illness-related anxieties are the main reasons that cancer patients turn to alternative remedies (13). Among 201 patients with established Parkinson’s disease, 40% used various forms of alternative medicine, most commonly herbals (14). An informal non-peer-reviewed survey of arthritis patients and their physicians found that 79% used or were interested in using alternative therapies, including herbs, chondroitin, glucosamine, massage, or chiropractic, but only 40% of users informed their physicians, and only 40% of physicians asked their patients about their alternative treatments. Reasons given for patients’ having not informed their physicians included fear of disapproval and the perception that the physician would be unable to provide advice on alternative approaches. One-third of the physicians felt they did not know enough to provide meaningful advice and 20% considered that alternative therapies were fraudulent, potentially harmful because they supplanted conventional therapy, and/or a waste of time and money. Most patients derived their information from advertising or Internet sources (15).

In summary, dietary supplement usage is widespread because of successful marketing strategies and popularization by word of mouth, advertising, and Internet information sources. Although certain patient groups, such as pregnant women, tend to have lower herbal usage than the average person, others with intractable chronic and/or fatal diseases, such as Parkinson’s, arthritis, and cancer, are more likely to turn to alternative therapies, particularly herbal supplements. Most striking, physicians are unlikely to ask and unlikely to be told of their patients’ herbal habits. In view of the uncertain composition of most herbs, their potential interaction with prescription drugs, and their propensity to cause side effects, widespread herbal usage poses a potentially significant risk to the health of patients.

What should practicing physicians be concerned about regarding herbals and other dietary supplements? A lot, as summarized in a recent editorial that emphasizes the differences between conventional and nonconventional medicine (16). Before the application of science to medicine in the early 20th century, botanicals were the major source of nonsurgical therapy. Practitioners of herbal medicine had no way of knowing the concentrations or purity of their remedies, and toxicities from such medicines as foxglove, opium, and cinchona bark were common. Proving the safety and efficacy of botanicals was not feasible until the advent of chemical approaches to identifying and ensuring the purity of active ingredients and of the scientific approach of well-controlled randomized clinical trials. Nevertheless, the burgeoning dietary supplement industry, with its lack of rigorous scientific testing, threatens to inundate the public with ineffective and potentially harmful remedies. In the absence of patent opportunities for dietary supplements, manufacturers have little incentive to prove the efficacy and safety of their products.

The literature on dietary supplements is vast and rife with reports of unsuspected toxicities from unregulated dietary supplements. The issue is complicated by the variety of regulations in different countries, where a botanical product may be classified as an approved medicine, a dietary supplement, or a recreational herb (17). Most nation members of the European Union regulate vitamins and minerals as foods if provided within the accepted recommended dietary allowances, but they have no specific regulations on dietary supplements as long as no medicinal claims are made (18). Several countries have established commissions to assess the safety and efficacy of herbals. For example, Commission E of the German Federal Health Agency has published more than 300 monographs that evaluate the efficacy and safety of different herbal products according to acceptable clinical trials (19). Ongoing reports of herbal toxicities may not appear in recent book form and must be sought in the current literature. For example, it has only recently been appreciated that fulminant hepatic failure may occur during the chronic use of kava (20, 21). Understanding potential efficacies and hazards of dietary supplements is a daunting task for practitioners. For example, the Physicians’ Desk Reference for Herbal Medicines lists 80 under letter A alone in its common name index and lists more than 350 side effects for all herbals (22). The recently published Physicians’ Desk Reference for Nuritional Supplements describes more than 200 nonherbal supplements (vitamins, minerals, amino acids, and other products) cross-referenced to more than 300 potential side effects (23). Given that herbals and nutritional supplements are taken by mouth, it is not surprising that the most common side effects relate to the gastrointestinal tract, including diarrhea, nausea, and vomiting. Because many plants have natural toxins that were developed for survival, hepatocellular damage is not uncommon after ingesting herbs, including comfrey, senna, and mixtures of ill-defined Chinese herbs (24). Additional problems arise from the presence of unregulated or unknown amounts of toxic substances within herbal preparations. For example, in a 1998 analysis of 251 Asian patent medicines performed by the California Department of Health Services, 10% were found to contain lead, 14% arsenic, and 14% mercury at potentially toxic levels (25). Others found toxic amounts of mercury in Chinese imported "herbal balls" and arsenic at levels that could result in daily accumulation of 73 mg arsenic and more than 1200 mg mercury (26). Aristolochia fangchi, or "birthwort," used for gastrointestinal symptoms, was strongly associated with nephropathy and development of urothelial carcinoma in women attending a Belgian weight reduction clinic (27, 28). Underscoring the problem of lack of quality control, 2 case reports described the symptoms and laboratory evidence of digitalis toxicity after ingestion of plantain, an herbal ingredient of a mixture claimed to "cleanse the body," that was contaminated with Digitalis lanata (29).

A recent survey indicated that 30% of patients undergoing surgery use herbal medications, about twice the usage in the general US population (30), and that 70% of herbal users failed to mention their use of dietary supplements in the routine preoperative evaluation (31). Preoperative herbal use is particularly hazardous, because different herbs may influence operative survival and/or alter the metabolism and pharmacologic effects of conventional anesthesia and postoperative drugs. For example, prolonged preoperative use of the immunostimulant echinacea may result in immunosuppression with prolonged wound healing and postoperative infections (32). Ephedra, a stimulant and the source of ephedrine and methamphetamine, increases blood pressure, heart rate, and risks of arrhythmias and vasospasm, which together increase the risks of myocardial infarction and stroke (33). In 1997 the FDA issued a warning on the use of ephedra as an herbal weight loss drug because of its potential adverse stimulant effects on both the circulatory and nervous systems (34). Although garlic lowers serum cholesterol to a modest amount (35), ajoene, a constituent of garlic, may potentiate platelet inhibitors and thereby increase the risk of bleeding complications of surgery (30). Ginkgo, used to enhance memory and improve peripheral vascular circulation, also has platelet-inhibiting properties that may result in intracellular hemorrhage and subdural hematomas (36, 37). Ginseng may lower postprandial blood glucose in type II diabetic patients but can induce hypoglycemia and inhibit platelet aggregation (38, 39). Kava, used for its sedative and antianxiety properties, can interact with barbiturates and benzodiazepines, prolonging sleep and even inducing coma (40), and has recently been associated with fulminant hepatic failure requiring liver transplantation (20, 21). A 2002 FDA consumer advisory cited 25 reports of liver-related injury in kava users and advises caution on its use, particularly in individuals with known liver disease (41). St John’s wort, used to prevent depression, inhibits serotonin reuptake, which results in serotonin excess and increases the metabolic rate of many cytochrome P450 drugs, including cyclosporin, midazolam, lidocaine, and warfarin, leading to their ineffectuality in therapeutic situations (30). Valerian, used for its sedative properties, potentiates the effects of benzodiazepines and may result in withdrawal delirium (42).

The health claims and potential side effects of some of the most commonly used herbals are shown in Table 1 (19, 22, 43, 44).


View this table:
TABLE 1 . Herbal supplements  
Functional Foods
In contrast to most dietary supplements, functional foods are components of the usual diet that may have special disease prevention attributes and are the topic of current traditional scientific investigation. According to the Food and Nutrition Board of the Institute of Medicine, a functional food is "any food or food ingredient that may provide a health benefit beyond the traditional nutrients it contains" (45). Unlike dietary supplements that can claim only general health benefits, functional foods may claim specific health benefits because they are considered part of the diet (46). The literature on functional foods is vast and growing exponentially, and this review can touch on only a few points that are essential for the practitioner. A recently published handbook provides excellent summaries (45).

Polyphenols and flavonoids
The term polyphenol encompasses simple phenols and flavonoids, which are found in fruits, vegetables, and nuts and their products, and possess important antioxidant properties. Flavonoids include proanthocyanidins, quercetin, and epicatechin, found mainly in chocolate, tea, and wine. Red wine also contains resveratrol, a nonpolyphenol antioxidant product of grape skins. The "French paradox" refers to the epidemiologic finding that the incidence of coronary heart disease was significantly lower in wine-drinking regions of France than in areas where wine was not the main alcoholic beverage (47). Subsequently, it was shown that wine phenols inhibited the oxidation of low-density lipoprotein (LDL) (48), an accepted reason for the preventive effect of polyphenols on the development of atherosclerosis. More recent studies demonstrate that the attenuation of coronary heart disease risk in wine drinkers is probably due as much to their lifestyle consumption of high amounts of polyphenol-containing fruits and vegetables as to wine (49). A 5-y prospective Dutch study of 800 elderly men found that the ingestion of flavonoids, mainly in tea, onions, and apples, was associated with significant reduction in mortality from coronary heart disease (50). In addition to antioxidant effects on LDL, other potentially cardioprotective effects of polyphenols include inhibition of platelet aggregation and vascular relaxation through the production of nitric oxide (51). Although polyphenols have the capacity to decrease LDL oxidation, inhibit platelet aggregation, and induce vascular relaxation, their clinical efficacy is modulated by many factors that include differences in wine and tea preparation, volatility, and absorbability. For example, green tea has a higher concentration of polphenols than black tea, which may be affected by the method of brewing (52). Wine should be consumed in moderation only, to avoid the chronic effects of alcohol. The year 2000 Dietary Guidelines for Americans identifies moderation as no more than 1 drink per day for women and 2 drinks per day for men, where a drink constitutes 5 oz of wine (53). Although these studies support the principle that fruits and vegetables should provide the main staple of a healthy diet, varied amounts of polyphenols in different foods and effects of food preparation and absorption hinder the establishment of clear-cut dietary and clinical recommendations of polyphenol-rich fruits and vegetables in the nutritional prevention of heart disease.

Soy isoflavones
Soy isoflavones are phytoestrogens that are derived from the protein fraction of the soybean and its food products (eg, soy milk, soy flour, tofu, miso), include genistein and daidzein, and possess estrogenic properties because of the similarities of their chemical structures to estrogenic compounds. Clinical trials identified the potential efficacy of soy isoflavones in the prevention of coronary heart disease, osteoporosis, and breast and prostate cancer. A meta-analysis of 37 clinical studies suggested that soy protein up to 45 g per day can lower serum cholesterol levels by 10% (54), but the long-term effects of soy on cardiac risk are unknown. Because phytoestrogens compete with estrogen for binding to estrogen receptors, their use could have beneficial effects in preventing osteoporosis and sex hormone–mediated malignancy, such as breast and prostate cancer. The clinical data are mixed and inconclusive on the effect of soy isoflavones on bone turnover and bone density (55). Data are mixed on whether soy isoflavones promote or protect against breast cancer (56–58), and one retrospective study of 1300 non-Asian women with breast cancer history found no association of phytoestrogen use and breast cancer risk (59). Although prostate cancer rates are lower in Eastern cultures where soy products play a major role in the diet, and although genistein inhibits the growth of prostate cancer cells, clinical studies to date have failed to demonstrate positive effects of dietary soy products on reducing the risk of prostate cancer (60).

Carotenoids
There are several plant-derived carotenoids in the human diet, of which ß-carotene, -carotene, lutein, zeaxanthin, and lycopene appear to have the most significance for health. Being lipid soluble, carotenoids are absorbed with fats and circulate bound to different lipoproteins. ß-carotene is a limited precursor of vitamin A, and excessive amounts of ß-carotene lead to reversible carotenemia but not to vitamin A toxicity. The principal biological effects of carotenoids relate to their antioxidant properties, which form the basis of potential protection against lipid peroxidation, atherogenesis, DNA oxidation, and cancer (61). Clinical studies suggest but have not yet proven that either ß-carotene or lycopene is cardioprotective (62, 63). Aortic atherosclerosis incidence was significantly inversely correlated with the intake of dietary lycopene in the Rotterdam study of 108 patients and control subjects (64). A review of more than 30 studies concluded that there is an inverse relationship between lycopene in tomato products and the risk of cancers of the prostate, lung, and stomach (65), and one study demonstrated a 21% reduction in prostate cancer with consumption of diets high in tomato-derived lycopene (66). A study of more than 25000 middle-aged male Finnish smokers found that the incidence of lung cancer was increased in those receiving ß-carotene supplements (67). In large cohorts followed over time, cataract formation was reduced significantly by dietary intake of fruits and vegetables rich in lutein and zeaxanthin (68, 69). Recent data suggest a potential preventive relationship between intake of these carotenoids and risk of macular degeneration (70).

Fish oils
Dietary fish oils appear as n-3 polyunsaturated fatty acids mainly in cold water fish, compared with n-6 polyunsaturates mainly from plants and saturated fatty acids from animal sources. Diets in which cold water fish such as mackerel, salmon, halibut, and trout are the main staple are associated with reduced incidence of coronary heart disease but increased risk of hemorrhage. Studies of susceptible men from Holland, Japan, and the United States showed that sudden death from coronary artery disease is reduced by half when 1–2 fish meals are consumed weekly (71–73). The biological effects of fish oils include inhibition of hepatic synthesis and secretion of triacylglycerol and very low density lipoprotein with reduced postprandial lipemia, increased circulating high-density lipoprotein, inhibition of platelet aggregation, and prevention of cardiac arrhythmias (73). Eicosapentaenoic acid (EPA) and its elongated product docosahexaenoic acid are the predominant fatty acids in fish, whereas -linolenic acid, the precursor of EPA, is found in canola, flaxseed, and walnut oils. A Mediterranean diet rich in these oils was found to reduce cardiac deaths by 70% in France (74). By virtue of anti-inflammatory properties and effects on cell membranes, fish oils are also thought to have a beneficial effect in the treatment of rheumatoid arthritis, although conclusive clinical studies are lacking (75).

Nuts
Although nuts are relatively high in fat, most of this fat is in the mono- or polyunsaturated form. Beneficial nuts include almonds, Brazil nuts, peanuts, walnuts, pistachios, and pecans. Three large prospective studies demonstrated that the consumption of 1–4 servings of nuts per week was associated with about a 40% reduction in risk of coronary heart disease, even after adjusting for conventional risk factors such as hypertension, smoking, diabetes, and hyperlipidemia (76–78). The purported beneficial effects of nuts include improvement of serum lipid profiles with a predicted 16% reduction in LDL cholesterol and presence of relatively high amounts of the nitric oxide precursor arginine, dietary fiber, and antioxidant vitamin E (78). Walnuts are particularly noteworthy for having a high content of n-3 linolenic acid (78).

Probiotics and prebiotics
Probiotics can be defined as "live microbial food supplements which benefit the host by improving the intestinal microbial form" (79). As such, probiotics can be consumed as either a functional food, such as a fermented milk product, or a supplement if provided separately in capsule or pill form. The rationale for probiotics is to improve intestinal immune tolerance to beneficial proteins and to maintain a normal immune intestinal barrier and permeability to exogenous foreign antigens (80). Intestinal organisms constitute the greatest cell population of the body, existing in 500 different species. Provision of normal human organisms that resist acid and bile destruction and adhere to the gut mucosa triggers a healthy immune response. The most beneficial organisms include those of the Lactobacillus and Bifidobacterium genera. Whereas controlled clinical trials are ongoing, beneficial effects have been reported in the treatment of food allergies, acute infant diarrheas, traveler’s diarrhea, antibiotic-associated colitis, and, potentially, inflammatory bowel disease (81). Prebiotics are "non-digestible food ingredients that selectively stimulate the growth of a limited number of bacteria in the colon" (82). More specifically, prebiotics are short-length carbohydrates, such as fructooligosaccharides, that resist digestion or are fermented in the colon to produce short-chain fatty acids, such as acetate, butyrate, and propionate, which have positive effects on colonic cell growth and stability, generate many of the same bacteria as provided in probiotics, and may promote improved bowel habit but also increased flatus (83).


SUMMARY AND CONCLUSIONS  
There are striking differences between dietary supplements and functional foods. Whereas dietary supplements, herbs in particular, are considered time-tested but are in most cases scientifically unproven, functional foods are components of the normal human diet that are increasingly shown by rigorous science to be inherently valuable for maintaining human health. Whereas herbal sales skyrocket and feed false public perception of the irrelevance of science to health, the era of functional foods promises to propel nutritional science to the forefront of preventive medicine for the most common diseases of humans. Together, this new era of nutrition presents imposing challenges to practitioners of medicine. It is incumbent on them to become fluent in the knowledge of commonly used herbals, including recognition of their potential benefits, side effects, and life-threatening effects when combined with certain drugs. Although advice-seeking patients typically have rudimentary knowledge of the ingredients and rationales for the herbs they ingest, physicians must be in a position of knowledge to maintain their patients’ confidence as a prerequisite to providing credible counsel. Furthermore, because most patients are curious and somewhat knowledgeable about their diets, physicians must establish a basic knowledge of conventional functional foods, which is viewed increasingly as an adjunct to sound medical advice. These are heady days for nutritional scientists as newer understandings of food and health promise to bring clinical nutrition to the forefront of clinical medicine. Practitioners must become nutritionally educated and oriented if they are to maintain their patients’ confidence and stay abreast of this aspect of continuously evolving modern medicine.


ACKNOWLEDGMENTS  
The author has no financial or personal potential or actual conflicts of interest with any manufacturer of herbal products or supplemental foods.


REFERENCES  

  1. Dietary Supplement Health and Education Act (DSHEA). 42 USC 287C–11. 1994.
  2. Zeisel SH. Regulation of "nutraceuticals." Science 1999;285:1853–5.
  3. Bean WB. Sir William Osler: aphorisms from his bedside teaching and writing. Springfield, IL: Charles C Thomas, 1968;1–164.
  4. Capasso L. 5300 years ago, the Ice Man used natural laxatives and antibiotics. Lancet 1998;352:1864 (letter).
  5. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001;135:594–600.
  6. US Food and Drug Administration. Statement by Joseph A. Levitt before the U.S. House of Representatives Committee on Government Reform. Internet: http://www.cfsan.fda.gov/lrd/st010320.html (accessed 20 March 2001).
  7. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998;280:1569–75.
  8. US Food and Drug Administration. Overview of dietary supplements. Internet: http://www.cfsan.fda.gov/dms/ds-oview.html (accessed 3 January 2001).
  9. Harnack LJ, Rydell SA, Stang J. Prevalence of use of herbal products by adults in the Minneapolis/St Paul, Minn, metropolitan area. Mayo Clin Proc 2001;76:688–94.
  10. Durante KM, Whitmore B, Jones CA, Campbell NR. Use of vitamins, minerals and herbs: a survey of patients attending family practice clinics. Clin Invest Med 2001;24:242–9.
  11. Gibson PS, Powrie R, Star J. Herbal and alternative medicine use during pregnancy: a cross-sectional survey. Obstet Gynecol 2001;97:S44–5.
  12. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733–9.
  13. Holland JC. Use of alternative medicine—a marker for distress? N Engl J Med 1999;340:1758–9.
  14. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson’s disease. Neurology 2001;57:790–4.
  15. Horstman J. The dangerous divide: why doctors aren’t asking and you aren’t telling. Arthritis Today 2002 June 28:34–44.
  16. Angell M, Kassirer JP. Alternative medicine—the risks of untested and unregulated remedies. N Engl J Med 1998;339:839–41.
  17. De Smet PA. Health risks of herbal remedies. Drug Safety 1995;13: 81–93.
  18. Mason P. Dietary supplements. 2nd ed. London: Pharmaceutical Press, 2001.
  19. Blumenthal M, Goldberg A, Brinckmann J. Herbal medicine: expanded Commission E monographs. Newton, MA: Integrative Medicine Communications, 2000.
  20. Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 2002;25:251–61.
  21. Kraft M, Spahn TW, Menzel J, et al. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch Med Wochenschr 2001;126:970–2.
  22. Physicians’ Desk Reference. PDR for herbal medicines. 1st ed. Montvale, NJ: Medical Economics, 1998.
  23. Physicians’ Desk Reference. PDR for nutritional supplements. 1st ed. Montvale, NJ: Medical Economics, 2001.
  24. Kaplowitz N. Hepatotoxicities of herbal remedies: insights into the intricacies of plant-animal warfare and cell death. Gastroenterology 1997;113:1408–12.
  25. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998; 339:847 (letter).
  26. Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995;333:803–4.
  27. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686–92.
  28. Kessler DA. Cancer and herbs. N Engl J Med 2000;342:1742–3.
  29. Slifman NR, Obermeyer WR, Aloi BK, et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 1998; 339:806–11.
  30. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208–16.
  31. Kaye AD, Clarke RC, Sabar R, et al. Herbal medicines: current trends in anesthesiology practice—a hospital survey. J Clin Anesth 2000;12: 468–71.
  32. Boullata JI, Nace AM. Safety issues with herbal medicine. Pharmacotherapy 2000;20:257–69.
  33. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833–8.
  34. US Food and Drug Administration. Dietary supplements containing ephedrine alkaloids: proposed rule. Fed Regist 1997;62:30678–717.
  35. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. Ann Intern Med 2000;133:420–9.
  36. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1933–4.
  37. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775–6.
  38. Vuksan V, Sievenpiper JL, Koo VY, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 2000;160:1009–13.
  39. Kimura Y, Okuda H, Arichi S. Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets. J Pharm Pharmacol 1988;40:838–43.
  40. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996;125:940–1.
  41. US Food and Drug Administration. Kava and severe liver injury. FDA Consum 2002;36:4 (letter).
  42. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998;280:1566–7.
  43. Tyler VE, Foster S. Tyler’s honest herbal: a sensible guide to the use of herbs and related remedies. 4th ed. New York: Haworth Herbal Press, 1999.
  44. Tyler VE, Robbers JE. Tyler’s herbs of choice: the therapeutic use of phytomedicinals. New York: Haworth Herbal Press, 1999.
  45. Wildman REC. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001.
  46. Ross S. Functional foods: the Food and Drug Administration perspective. Am J Clin Nutr 2000;71(suppl):1735S–8S; discussion 1739S–42S.
  47. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523–6.
  48. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993;341:454–7.
  49. Tjonneland A, Gronbaek M, Stripp C, Overvad K. Wine intake and diet in a random sample of 48763 Danish men and women. Am J Clin Nutr 1999;69:49–54.
  50. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007–11.
  51. Dubick M, Omaye ST. Modification of atherogenesis and heart disease by grape wine and tea polyphenols. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001:235–60.
  52. Prior RL, Cao G. Antioxidant capacity and polyphenolic components of teas: implications for altering in vivo antioxidant status. Proc Soc Exp Biol Med 1999;220:255–61.
  53. Dietary Guidelines Advisory Committee. Report of the Dietary Guidelines Advisory Committee on Dietary Guidelines for Americans. 5th ed. Washington, DC: US Department of Agriculture, 2000.
  54. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276–82.
  55. Messina M, Gugger ET, Alekel DL. Soy protein, soybean isoflavones, and bone health: a review of the animal and human data. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001:77–98.
  56. Sirtori CR. Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Safety 2001;24:665–82.
  57. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001;35:1118–21.
  58. Kurzer MS. Hormonal effects of soy in premenopausal women and men. J Nutr 2002;132:570S–3S.
  59. Horn-Ross PL, John EM, Lee M, et al. Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001;154:434–41.
  60. Mitchell J. Phytoestrogens: involvement in breast and prostate cancer. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001:99–111.
  61. Faulks RM, Southon S. Carotenoids, metabolism and disease. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001:143–56.
  62. Gale CR, Ashurst HE, Powers HJ, Martyn CN. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr 2001;74:402–8.
  63. Arab L, Steck S. Lycopene and cardiovascular disease. Am J Clin Nutr 2000;71(suppl):1691S–5S; discussion 1696S–7S.
  64. Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JC. Serum carotenoids and atherosclerosis: the Rotterdam Study. Atherosclerosis 2000;148:49–56.
  65. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317–31.
  66. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767–76.
  67. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560–70.
  68. Chasan-Taber L, Willett WC, Seddon JM, et al. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. Am J Clin Nutr 1999;70:509–16.
  69. Brown L, Rimm EB, Seddon JM, et al. A prospective study of carotenoid intake and risk of cataract extraction in US men. Am J Clin Nutr 1999;70:517–24.
  70. Johnson EJ, Hammond BR, Yeum KJ, et al. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr 2000;71:1555–62.
  71. Albert CM, Hennekens CH, O’Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23–8.
  72. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205–9.
  73. Connor WE. n-3 Fatty acids from fish and fish oil: panacea or nostrum? Am J Clin Nutr 2001;74:415–6.
  74. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454–9.
  75. Volker DH, Garg ML. n-3 polyunsaturated fatty acids and rheumatoid arthritis. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001:353–76.
  76. Fraser GE, Lindsted KD, Beeson WL. Effect of risk factor values on lifetime risk of and age at first coronary event: the Adventist Health Study. Am J Epidemiol 1995;142:746–58.
  77. Hu FB, Stampfer MJ. Nut consumption and risk of coronary heart disease: a review of epidemiologic evidence. Curr Atheroscler Rep 1999;1:204–9.
  78. Sabate J, Radak T, Brown J. The role of nuts in cardiovascular disease prevention. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. Boca Raton, FL: CRC Press, 2001:477–95.
  79. Dunne C, O’Mahony L, Murphy L, et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 2001;73(suppl):386S–92S.
  80. Isolauri E. Probiotics in human disease. Am J Clin Nutr 2001; 73(suppl):1142S–6S.
  81. Saavedra JM. Clinical applications of probiotic agents. Am J Clin Nutr 2001;73(suppl):1147S–51S.
  82. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr 2001;73(suppl):361S–4S.
  83. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. Am J Clin Nutr 2001;73(suppl):415S–20S.

作者: Charles H Halsted
医学百科App—中西医基础知识学习工具
  • 相关内容
  • 近期更新
  • 热文榜
  • 医学百科App—健康测试工具